AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer

Abstract Background Prostate cancer(PCa) is the most commonly occurring male cancer in the USA. Abiraterone or Enzalutamide have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). However, the treatment-emergent neuroendocrine PCa (t-NEPC) may develop, resulti...

Full description

Bibliographic Details
Main Authors: Linglong Yin, Yubing Ye, Ling Zou, Jinli Lin, Yi Dai, Yongming Fu, Youhong Liu, Yuchong Peng, Yingxue Gao, Yuxin Fu, Xuli Qi, Tanggang Deng, Songwei Zhang, Xiong Li
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
AR Antagonists
Drug Resistance
TOMM20
Autophagic Degradation
Neuroendocrine Prostate Cancer
Online Access:https://doi.org/10.1186/s13046-023-02776-0

Internet

https://doi.org/10.1186/s13046-023-02776-0

Similar Items